Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

on behalf of the COVID-19 and Cancer Consortium

doi:10.3390/cancers14174334

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

on behalf of the COVID-19 and Cancer Consortium

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. Results: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity. Conclusions: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.

Original language	English (US)
Article number	4334
Journal	Cancers
Volume	14
Issue number	17
DOIs	https://doi.org/10.3390/cancers14174334
State	Published - Sep 2022

Bibliographical note

Funding Information:
M.J.W.—Advisory board Deciphera, Adaptimmune, Epizyme; L.F.—research funding to institution: BMS, Kartos, EMD Serono/Pfizer, Array/Pfizer. Consultant: Else-vier. All outside submitted work; J.C.T.—Blueprint, Deciphera, Bayer, c4 therapeutics, Aadi, Foghorn, Daiichi-Sankyo, Adcendo; A.A.K.—stock ownership Merck, Fate Therapeutics, Exact Sciences, Gilead Sciences, Novavaxi, advisory board Genentech, Research funding to institution Astra Zeneca; A.R.K.—Within the last three years (all unrelated to this manuscript): stock ownership Merck and Sanofi; honoraria from MJH Life Sciences/OncLive and HMP Global; research collaborations with Tempus Labs and Natera; Uncompensated advisory board with Seagen/Astellas; E.A.G.—Honoraria to EAG—Abbvie, Alexion Pharmaceuticals, Genentech, Novartis, CTI biopharma, Apellis, Celgene/BMS, Takeda Oncology, Taiho Oncology, Physician Educational Resource, Med-iCom Worldwide, American Society of Hematology, Picnic Health, AAMDSIF; Research Support to Roswell Park: Astex Pharmaceuticals, Genentech, Blueprint Medicine, Alexion Pharmaceuticals, Apellis, BMS/Celgene, Celldex Therapeutics; I.P.—Within the last three years (all unrelated to this manuscript): consultant fees from Regeneron, Oncorus, Iovance, and Nouscom; stock options from Seneca Therapeutics; W.T.—Personal fees from Eli Lilly, EMD Serono, Mundipharma, C4 Therapeutics, Daiichi Sankyo, Blueprint, Agios Pharmaceuticals, Deciphera, Adcendo, Ayala Pharmaceuticals, Kowa, Servier, Bayer Pharmaceuticals, Epizyme, Cogent, Medpacto, Foghorn Therapeutics, Amgen, AmMax Bio, outside the submitted work; patent Companion Diagnostic for CDK4 inhibitors - 14/854,329 pending to MSKCC/SKI, and a patent Enigma and CDH18 as companion Diagnostics for CDK4 inhibition–SKI2016-021-03 pending to MSKCC/SKI and Scientific Advisory Board - Certis Oncology Solutions, Stock Ownership, Co-Founder - Atropos Therapeutics, Stock Ownership, Scientific Advisory Board Innova Therapeutics; C.H.—Stock holdings in Johnson and Johnson; research funding to institution from Merck, Bausch Health, Genentech, Bayer, and AstraZeneca, consultant fees from Tempus, Genzyme, and EMD Sorono, speaking fees from OncLive/MJH Life Sciences, travel fees from Merck, all outside the submitted work; SRJ—institutional research funding from Varian Medical Systems; M.J.—Research grant—Astrazeneca, Pfizer, Eisai, Advisory board for Seagen, Sanofi; A.K.—Stock holdings Fate Therapeutics, Exact Sciences, Gilead Sciences, Mitati Therapeutics, Novavax; Research funding to institution from Astra Zeneca, Advisory board: Genentech; K.E.—Honoraria from BMS, Pfizer, Merck, Roche, EMD Serono, Astrazeneca, Ipsen, Sanofi, all outside submitted work. Research grants from Pfizer, outside submitted work; L.P.—workshop-Curio Science; advisory board-Epizyme; P.G.—consulting: 4D Pharma PLC, Astellas Pharma, AstraZeneca, Boston Gene, Bristol Myers Squibb, Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech, Gilead Sciences, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, Merck, Mirati Therapeutics, Pfizer, Puretech, QED Therapeutics, Regeneron Pharmaceuticals, Roche, Seattle Genetics, Silverback Therapeutics, Uro-Gen; institutional research funding: Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm Group, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck, Mirati Therapeutics, Pfizer, QED Therapeutics; J.L.W.—Consulting-Westat, Roche, Flatiron Health, Melax Tech, outside the submitted work; Ownership-HemOnc.org LLC, outside the submitted work.; E.J.D.- Consulting with Deciphera and Aadi, Speaking fees MJH Life Sciences, Research funding to institution Karyopharm, Top Alliance Biosciences, Cogent, Inhibrx, Actuate, BioAtla, Cornerstone, Incyte; C.H., S.C., B.F., A.B., D.V., E.R., M.I., G.K.S., C.A.P., R.C., C.P., O.Z., V.S., L.T., E.N., E.T.L., C.L., R.M.S., R.R.M., A.A., S.T., B.H., A.A.K., D.Y.R., G.N., H.P., D.K., M.A.B., D.P.S. declared no conflicts relevant to this manuscript. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Funding Information:
REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/National Institute of Health (NIH)). This study was partly supported by grant number P30 CA068485 from the National Cancer Institute to Vanderbilt University Medical Center. Igor Puzanov is supported by NIH (P30CA016056). Petros Grivas is supported by NIH (P30CA015704). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication.

Publisher Copyright:
© 2022 by the authors.

Keywords

CCC19
COVID-19
SARS-CoV-2
sarcoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.3390/cancers14174334

Find It

Find It at U of M Libraries

Cite this

@article{87928aea42d44c0daa6f1bd7a39d9b2c,

title = "Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study",

abstract = "Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. Results: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity. Conclusions: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.",

keywords = "CCC19, COVID-19, SARS-CoV-2, sarcoma",

author = "{on behalf of the COVID-19 and Cancer Consortium} and Wagner, {Michael J.} and Cassandra Hennessy and Alicia Beeghly and Benjamin French and Shah, {Dimpy P.} and Sarah Croessmann and Diana Vilar-Compte and Erika Ruiz-Garcia and Matthew Ingham and Schwartz, {Gary K.} and Painter, {Corrie A.} and Rashmi Chugh and Leslie Fecher and Cathleen Park and Olga Zamulko and Trent, {Jonathan C.} and Vivek Subbiah and Khaki, {Ali Raza} and Lisa Tachiki and Nakasone, {Elizabeth S.} and Loggers, {Elizabeth T.} and Chris Labaki and Saliby, {Renee Maria} and McKay, {Rana R.} and Archana Ajmera and Griffiths, {Elizabeth A.} and Igor Puzanov and Tap, {William D.} and Clara Hwang and Sheela Tejwani and Jhawar, {Sachin R.} and Brandon Hayes-Lattin and Elizabeth Wulff-Burchfield and Anup Kasi and Reuben, {Daniel Y.} and Gayathri Nagaraj and Monika Joshi and Hyma Polimera and Kulkarni, {Amit A.} and Khashayar Esfahani and Kwon, {Daniel H.} and Luca Paoluzzi and Bilen, {Mehmet A.} and Durbin, {Eric B.} and Petros Grivas and Warner, {Jeremy L.} and Davis, {Elizabeth J.}",

note = "Funding Information: M.J.W.—Advisory board Deciphera, Adaptimmune, Epizyme; L.F.—research funding to institution: BMS, Kartos, EMD Serono/Pfizer, Array/Pfizer. Consultant: Else-vier. All outside submitted work; J.C.T.—Blueprint, Deciphera, Bayer, c4 therapeutics, Aadi, Foghorn, Daiichi-Sankyo, Adcendo; A.A.K.—stock ownership Merck, Fate Therapeutics, Exact Sciences, Gilead Sciences, Novavaxi, advisory board Genentech, Research funding to institution Astra Zeneca; A.R.K.—Within the last three years (all unrelated to this manuscript): stock ownership Merck and Sanofi; honoraria from MJH Life Sciences/OncLive and HMP Global; research collaborations with Tempus Labs and Natera; Uncompensated advisory board with Seagen/Astellas; E.A.G.—Honoraria to EAG—Abbvie, Alexion Pharmaceuticals, Genentech, Novartis, CTI biopharma, Apellis, Celgene/BMS, Takeda Oncology, Taiho Oncology, Physician Educational Resource, Med-iCom Worldwide, American Society of Hematology, Picnic Health, AAMDSIF; Research Support to Roswell Park: Astex Pharmaceuticals, Genentech, Blueprint Medicine, Alexion Pharmaceuticals, Apellis, BMS/Celgene, Celldex Therapeutics; I.P.—Within the last three years (all unrelated to this manuscript): consultant fees from Regeneron, Oncorus, Iovance, and Nouscom; stock options from Seneca Therapeutics; W.T.—Personal fees from Eli Lilly, EMD Serono, Mundipharma, C4 Therapeutics, Daiichi Sankyo, Blueprint, Agios Pharmaceuticals, Deciphera, Adcendo, Ayala Pharmaceuticals, Kowa, Servier, Bayer Pharmaceuticals, Epizyme, Cogent, Medpacto, Foghorn Therapeutics, Amgen, AmMax Bio, outside the submitted work; patent Companion Diagnostic for CDK4 inhibitors - 14/854,329 pending to MSKCC/SKI, and a patent Enigma and CDH18 as companion Diagnostics for CDK4 inhibition–SKI2016-021-03 pending to MSKCC/SKI and Scientific Advisory Board - Certis Oncology Solutions, Stock Ownership, Co-Founder - Atropos Therapeutics, Stock Ownership, Scientific Advisory Board Innova Therapeutics; C.H.—Stock holdings in Johnson and Johnson; research funding to institution from Merck, Bausch Health, Genentech, Bayer, and AstraZeneca, consultant fees from Tempus, Genzyme, and EMD Sorono, speaking fees from OncLive/MJH Life Sciences, travel fees from Merck, all outside the submitted work; SRJ—institutional research funding from Varian Medical Systems; M.J.—Research grant—Astrazeneca, Pfizer, Eisai, Advisory board for Seagen, Sanofi; A.K.—Stock holdings Fate Therapeutics, Exact Sciences, Gilead Sciences, Mitati Therapeutics, Novavax; Research funding to institution from Astra Zeneca, Advisory board: Genentech; K.E.—Honoraria from BMS, Pfizer, Merck, Roche, EMD Serono, Astrazeneca, Ipsen, Sanofi, all outside submitted work. Research grants from Pfizer, outside submitted work; L.P.—workshop-Curio Science; advisory board-Epizyme; P.G.—consulting: 4D Pharma PLC, Astellas Pharma, AstraZeneca, Boston Gene, Bristol Myers Squibb, Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech, Gilead Sciences, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, Merck, Mirati Therapeutics, Pfizer, Puretech, QED Therapeutics, Regeneron Pharmaceuticals, Roche, Seattle Genetics, Silverback Therapeutics, Uro-Gen; institutional research funding: Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm Group, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck, Mirati Therapeutics, Pfizer, QED Therapeutics; J.L.W.—Consulting-Westat, Roche, Flatiron Health, Melax Tech, outside the submitted work; Ownership-HemOnc.org LLC, outside the submitted work.; E.J.D.- Consulting with Deciphera and Aadi, Speaking fees MJH Life Sciences, Research funding to institution Karyopharm, Top Alliance Biosciences, Cogent, Inhibrx, Actuate, BioAtla, Cornerstone, Incyte; C.H., S.C., B.F., A.B., D.V., E.R., M.I., G.K.S., C.A.P., R.C., C.P., O.Z., V.S., L.T., E.N., E.T.L., C.L., R.M.S., R.R.M., A.A., S.T., B.H., A.A.K., D.Y.R., G.N., H.P., D.K., M.A.B., D.P.S. declared no conflicts relevant to this manuscript. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Funding Information: REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/National Institute of Health (NIH)). This study was partly supported by grant number P30 CA068485 from the National Cancer Institute to Vanderbilt University Medical Center. Igor Puzanov is supported by NIH (P30CA016056). Petros Grivas is supported by NIH (P30CA015704). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/cancers14174334",

language = "English (US)",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "17",

}

TY - JOUR

T1 - Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19

T2 - A CCC19-Registry Based Retrospective Cohort Study

AU - on behalf of the COVID-19 and Cancer Consortium

AU - Wagner, Michael J.

AU - Hennessy, Cassandra

AU - Beeghly, Alicia

AU - French, Benjamin

AU - Shah, Dimpy P.

AU - Croessmann, Sarah

AU - Vilar-Compte, Diana

AU - Ruiz-Garcia, Erika

AU - Ingham, Matthew

AU - Schwartz, Gary K.

AU - Painter, Corrie A.

AU - Chugh, Rashmi

AU - Fecher, Leslie

AU - Park, Cathleen

AU - Zamulko, Olga

AU - Trent, Jonathan C.

AU - Subbiah, Vivek

AU - Khaki, Ali Raza

AU - Tachiki, Lisa

AU - Nakasone, Elizabeth S.

AU - Loggers, Elizabeth T.

AU - Labaki, Chris

AU - Saliby, Renee Maria

AU - McKay, Rana R.

AU - Ajmera, Archana

AU - Griffiths, Elizabeth A.

AU - Puzanov, Igor

AU - Tap, William D.

AU - Hwang, Clara

AU - Tejwani, Sheela

AU - Jhawar, Sachin R.

AU - Hayes-Lattin, Brandon

AU - Wulff-Burchfield, Elizabeth

AU - Kasi, Anup

AU - Reuben, Daniel Y.

AU - Nagaraj, Gayathri

AU - Joshi, Monika

AU - Polimera, Hyma

AU - Kulkarni, Amit A.

AU - Esfahani, Khashayar

AU - Kwon, Daniel H.

AU - Paoluzzi, Luca

AU - Bilen, Mehmet A.

AU - Durbin, Eric B.

AU - Grivas, Petros

AU - Warner, Jeremy L.

AU - Davis, Elizabeth J.

N1 - Funding Information: M.J.W.—Advisory board Deciphera, Adaptimmune, Epizyme; L.F.—research funding to institution: BMS, Kartos, EMD Serono/Pfizer, Array/Pfizer. Consultant: Else-vier. All outside submitted work; J.C.T.—Blueprint, Deciphera, Bayer, c4 therapeutics, Aadi, Foghorn, Daiichi-Sankyo, Adcendo; A.A.K.—stock ownership Merck, Fate Therapeutics, Exact Sciences, Gilead Sciences, Novavaxi, advisory board Genentech, Research funding to institution Astra Zeneca; A.R.K.—Within the last three years (all unrelated to this manuscript): stock ownership Merck and Sanofi; honoraria from MJH Life Sciences/OncLive and HMP Global; research collaborations with Tempus Labs and Natera; Uncompensated advisory board with Seagen/Astellas; E.A.G.—Honoraria to EAG—Abbvie, Alexion Pharmaceuticals, Genentech, Novartis, CTI biopharma, Apellis, Celgene/BMS, Takeda Oncology, Taiho Oncology, Physician Educational Resource, Med-iCom Worldwide, American Society of Hematology, Picnic Health, AAMDSIF; Research Support to Roswell Park: Astex Pharmaceuticals, Genentech, Blueprint Medicine, Alexion Pharmaceuticals, Apellis, BMS/Celgene, Celldex Therapeutics; I.P.—Within the last three years (all unrelated to this manuscript): consultant fees from Regeneron, Oncorus, Iovance, and Nouscom; stock options from Seneca Therapeutics; W.T.—Personal fees from Eli Lilly, EMD Serono, Mundipharma, C4 Therapeutics, Daiichi Sankyo, Blueprint, Agios Pharmaceuticals, Deciphera, Adcendo, Ayala Pharmaceuticals, Kowa, Servier, Bayer Pharmaceuticals, Epizyme, Cogent, Medpacto, Foghorn Therapeutics, Amgen, AmMax Bio, outside the submitted work; patent Companion Diagnostic for CDK4 inhibitors - 14/854,329 pending to MSKCC/SKI, and a patent Enigma and CDH18 as companion Diagnostics for CDK4 inhibition–SKI2016-021-03 pending to MSKCC/SKI and Scientific Advisory Board - Certis Oncology Solutions, Stock Ownership, Co-Founder - Atropos Therapeutics, Stock Ownership, Scientific Advisory Board Innova Therapeutics; C.H.—Stock holdings in Johnson and Johnson; research funding to institution from Merck, Bausch Health, Genentech, Bayer, and AstraZeneca, consultant fees from Tempus, Genzyme, and EMD Sorono, speaking fees from OncLive/MJH Life Sciences, travel fees from Merck, all outside the submitted work; SRJ—institutional research funding from Varian Medical Systems; M.J.—Research grant—Astrazeneca, Pfizer, Eisai, Advisory board for Seagen, Sanofi; A.K.—Stock holdings Fate Therapeutics, Exact Sciences, Gilead Sciences, Mitati Therapeutics, Novavax; Research funding to institution from Astra Zeneca, Advisory board: Genentech; K.E.—Honoraria from BMS, Pfizer, Merck, Roche, EMD Serono, Astrazeneca, Ipsen, Sanofi, all outside submitted work. Research grants from Pfizer, outside submitted work; L.P.—workshop-Curio Science; advisory board-Epizyme; P.G.—consulting: 4D Pharma PLC, Astellas Pharma, AstraZeneca, Boston Gene, Bristol Myers Squibb, Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech, Gilead Sciences, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, Merck, Mirati Therapeutics, Pfizer, Puretech, QED Therapeutics, Regeneron Pharmaceuticals, Roche, Seattle Genetics, Silverback Therapeutics, Uro-Gen; institutional research funding: Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm Group, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck, Mirati Therapeutics, Pfizer, QED Therapeutics; J.L.W.—Consulting-Westat, Roche, Flatiron Health, Melax Tech, outside the submitted work; Ownership-HemOnc.org LLC, outside the submitted work.; E.J.D.- Consulting with Deciphera and Aadi, Speaking fees MJH Life Sciences, Research funding to institution Karyopharm, Top Alliance Biosciences, Cogent, Inhibrx, Actuate, BioAtla, Cornerstone, Incyte; C.H., S.C., B.F., A.B., D.V., E.R., M.I., G.K.S., C.A.P., R.C., C.P., O.Z., V.S., L.T., E.N., E.T.L., C.L., R.M.S., R.R.M., A.A., S.T., B.H., A.A.K., D.Y.R., G.N., H.P., D.K., M.A.B., D.P.S. declared no conflicts relevant to this manuscript. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Funding Information: REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/National Institute of Health (NIH)). This study was partly supported by grant number P30 CA068485 from the National Cancer Institute to Vanderbilt University Medical Center. Igor Puzanov is supported by NIH (P30CA016056). Petros Grivas is supported by NIH (P30CA015704). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. Publisher Copyright: © 2022 by the authors.

PY - 2022/9

Y1 - 2022/9

N2 - Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. Results: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity. Conclusions: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.

AB - Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. Results: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity. Conclusions: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.

KW - CCC19

KW - COVID-19

KW - SARS-CoV-2

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85137928768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137928768&partnerID=8YFLogxK

U2 - 10.3390/cancers14174334

DO - 10.3390/cancers14174334

M3 - Article

C2 - 36077869

AN - SCOPUS:85137928768

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 17

M1 - 4334

ER -

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this